According to the World Health Organization (WHO), approximately 296 million people globally live with hepatitis B, with most unaware of their infection.
Gilead Sciences is planning to file for approval of Hepcludex, its antiviral therapy for rare hepatitis D virus (HDV) in the US later this year, after the drug's safety and efficacy was sho
India’s Zydus Cadila wants to test a form of interferon, usually used against hepatitis B and C, as a potential treatment for the virus that causes COVID-19.
American pharma firm AbbVie is taking NHS England to court over a procurement process aimed to help England become the first country in the world to eradicate the hepatitis C virus (HCV). <